Idiopathic pulmonary fibrosis: classification, epidemiology, course and prognosis Source: International Congress 2016 – Russia Session Year: 2016
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015
Idiopathic pulmonary fibrosis (IPF): epidemiology, biology, diagnosis and treatment Source: Virtual Congress 2020 – When the lung gets stiff Year: 2020
Interstitial lung diseases in childhood Source: ISSN=1025-448x, ISBN=1-904097-22-7, page=213 Year: 2002
Idiopathic pulmonary hemosiderosis in childhood – review of 43 cases Source: Eur Respir J 2006; 28: Suppl. 50, 263s Year: 2006
A rare case of idiopathic pulmonary fibrosis in children Source: Eur Respir J 2007; 30: Suppl. 51, 390s Year: 2007
Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Source: Eur Respir J 2007; 30: 835-839 Year: 2007
PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery Source: Eur Respir Rev 2013; 22: 148-152 Year: 2013
Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features Source: Eur Respir J 2006; 27: 143-150 Year: 2006
Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015
Familial cases of idiopathic pulmonary fibrosis: Clinical observation Source: Annual Congress 2011 - Genetic and molecular background in pulmonary fibrosis Year: 2011
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016
Idiopathic pulmonary haemosiderosis in children –cases with long survival Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015
Vulnerability of fatal infection under steroid treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2002; 20: Suppl. 38, 354s Year: 2002
Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study Source: Eur Respir J 2012; 40: 101-109 Year: 2012
Seasonal epidemiology and clinical manifestations of interstitial lung diseases (ILD) as an important criterion for differential diagnosis viral pneumonia with pulmonary arterial hypertention (PAH) associated with severe COVID-19. Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021
Idiopathic pulmonary fibrosis and pregnancy: a case controlled study Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009
Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009
The epidemiologic features and the patterns of medical resource use in idiopathic pulmonary fibrosis (IPF) in Korea Source: International Congress 2015 – IPF: clinical aspects Year: 2015